Mechanisms of damage and therapies for cardiac amyloidosis : a role for inflammation?
Heusch, Gerd (University of Duisburg-Essen)
Kleinbongard, Petra (University of Duisburg-Essen)
Podesser, B.K. (Medical University of Vienna)
Vilahur, Gemma (Institut de Recerca Sant Pau)
Bellofatto, Ilaria Anna (University of Genoa)
Efstathia Nikolaou, Panagiota (National and Kapodistrian University of Athens)
Andreadou, Ioanna (University of Athens)
Canepa, Marco (IRCCS Ospedale Policlinico San Martino (Gènova, Itàlia))
Carbone, Federico (IRCCS Ospedale Policlinico San Martino Genoa-Italian Cardiovascular Network)
Ghigo, Alessandra (University of Torino)
Maack, Christoph (University Clinic Würzburg)
Stamatelopoulos, Kimon (National and Kapodistrian University of Athens)
Stellos, Konstantinos (Heidelberg University)
Montecucco, Fabrizio (IRCCS Ospedale Policlinico San Martino Genoa-Italian Cardiovascular Network)
Liberale, Luca (IRCCS Ospedale Policlinico San Martino Genoa-Italian Cardiovascular Network)
Universitat Autònoma de Barcelona. Departament de Medicina

Data:	2024
Resum:	The term cardiac amyloidosis (CA) refers to the accumulation of extracellular amyloid deposits in the heart because of different conditions often affecting multiple organs including brain, kidney and liver. Notably, cardiac involvement significantly impacts prognosis of amyloidosis, with cardiac biomarkers playing a pivotal role in prognostic stratification. Therapeutic management poses a challenge due to limited response to conventional heart failure therapies, necessitating targeted approaches aimed at preventing, halting or reversing amyloid deposition. Mechanisms underlying organ damage in CA are multifactorial, involving proteotoxicity, oxidative stress, and mechanical interference. While the role of inflammation in CA remains incompletely understood, emerging evidence suggests its potential contribution to disease progression as well as its utility as a therapeutic target. This review reports on the cardiac involvement in systemic amyloidosis, its prognostic role and how to assess it. Current and emerging therapies will be critically discussed underscoring the need for further efforts aiming at elucidating CA pathophysiology. The emerging evidence suggesting the contribution of inflammation to disease progression and its prognostic role will also be reviewed possibly offering insights into novel therapeutic avenues for CA.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Amyloidosis ; Cardiac amyloidosis ; Inflammation ; Light chain amyloidosis ; Transthyretin amyloidosis
Publicat a:	Clinical Research in Cardiology, 2024 , ISSN 1861-0692

DOI: 10.1007/s00392-024-02522-2
PMID: 39167195

15 p, 1.0 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats